MX2021013582A - Composiciones que comprenden agentes biologicamente activos y sales biliares. - Google Patents
Composiciones que comprenden agentes biologicamente activos y sales biliares.Info
- Publication number
- MX2021013582A MX2021013582A MX2021013582A MX2021013582A MX2021013582A MX 2021013582 A MX2021013582 A MX 2021013582A MX 2021013582 A MX2021013582 A MX 2021013582A MX 2021013582 A MX2021013582 A MX 2021013582A MX 2021013582 A MX2021013582 A MX 2021013582A
- Authority
- MX
- Mexico
- Prior art keywords
- biologically active
- active agents
- compositions
- bile salts
- absorption
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente invención se divulgan composiciones capaces de mejorar la liberación y absorción de agentes biológicamente activos cuando se administran a un sujeto. Además, se divulgan métodos para aumentar la absorción in vivo de agentes biológicamente activos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962850509P | 2019-05-20 | 2019-05-20 | |
PCT/US2020/033577 WO2020236802A1 (en) | 2019-05-20 | 2020-05-19 | Compositions comprising biologically active agents and bile salts |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021013582A true MX2021013582A (es) | 2021-12-10 |
Family
ID=73459443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021013582A MX2021013582A (es) | 2019-05-20 | 2020-05-19 | Composiciones que comprenden agentes biologicamente activos y sales biliares. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220160731A1 (es) |
EP (1) | EP3972582A4 (es) |
JP (1) | JP2022533837A (es) |
AU (1) | AU2020279976A1 (es) |
CA (1) | CA3137919A1 (es) |
MX (1) | MX2021013582A (es) |
WO (1) | WO2020236802A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022013090A (es) * | 2020-04-20 | 2022-11-14 | Poviva Corp | Composiciones y metodos para el suministro mejorado de agentes antivirales. |
WO2024010629A1 (en) * | 2022-07-05 | 2024-01-11 | Poviva Corp | Compositions and methods for treating hypertension |
US11666544B1 (en) * | 2022-07-05 | 2023-06-06 | Poviva Corp. | Compositions and methods for treating hypertension |
US11980593B2 (en) * | 2022-07-05 | 2024-05-14 | Poviva Corp. | Compositions and methods for treating hypertension |
US20240009140A1 (en) * | 2022-07-05 | 2024-01-11 | Poviva Corp | Pharmaceutical compositions and methods for treating hypertension |
US11944635B1 (en) | 2023-07-24 | 2024-04-02 | Poviva Corp | Compositions and methods for treating epilepsy |
US11931369B1 (en) * | 2023-07-24 | 2024-03-19 | Poviva Corp | Compositions and methods for treating epilepsy |
US11986485B1 (en) | 2023-07-24 | 2024-05-21 | Poviva Corp | Compositions and methods for treating epilepsy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8909022D0 (en) * | 1989-04-20 | 1989-06-07 | Cortecs Ltd | Pharmaceutical compositions |
NZ270145A (en) * | 1994-03-01 | 1996-08-27 | Lilly Co Eli | Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent |
US5616342A (en) * | 1995-04-11 | 1997-04-01 | Pdt, Inc. | Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof |
EP1539069A4 (en) * | 2002-05-31 | 2007-11-14 | Univ Mississippi | TRANSMUCOSAL DELIVERY OF CANNABINOIDS |
PL2155229T3 (pl) * | 2007-05-01 | 2011-06-30 | Cephalon Inc | Kompozycja do przezśluzkowego podawania polipeptydów |
US20140166028A1 (en) * | 2012-12-14 | 2014-06-19 | Richard C. Fuisz | Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor or Smoke Producing Device Through Use of an Absorption Conditioning Unit |
US20170071966A1 (en) * | 2014-05-13 | 2017-03-16 | Steven Baranowitz | Pharmaceutical composition |
WO2015183984A2 (en) * | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including tocopherol and uses thereof |
WO2015191728A1 (en) * | 2014-06-11 | 2015-12-17 | Poviva Tea, Llc | Food and beverage compositions infused with lipophilic active agents and methods of use thereof |
AU2016367036B2 (en) * | 2015-12-09 | 2019-04-18 | Poviva Corp. | Methods for formulating orally ingestible compositions comprising lipophilic active agents |
-
2020
- 2020-05-19 JP JP2021569075A patent/JP2022533837A/ja active Pending
- 2020-05-19 EP EP20810110.5A patent/EP3972582A4/en active Pending
- 2020-05-19 AU AU2020279976A patent/AU2020279976A1/en not_active Abandoned
- 2020-05-19 US US17/053,529 patent/US20220160731A1/en not_active Abandoned
- 2020-05-19 MX MX2021013582A patent/MX2021013582A/es unknown
- 2020-05-19 WO PCT/US2020/033577 patent/WO2020236802A1/en unknown
- 2020-05-19 CA CA3137919A patent/CA3137919A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3972582A4 (en) | 2023-10-04 |
CA3137919A1 (en) | 2020-11-26 |
EP3972582A1 (en) | 2022-03-30 |
US20220160731A1 (en) | 2022-05-26 |
JP2022533837A (ja) | 2022-07-26 |
AU2020279976A1 (en) | 2021-11-11 |
WO2020236802A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021013582A (es) | Composiciones que comprenden agentes biologicamente activos y sales biliares. | |
MX2021006912A (es) | Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas. | |
PH12021551279A1 (en) | Modified amine lipids | |
MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
NZ702799A (en) | Methods and compositions for cns delivery of arylsulfatase a | |
NZ606825A (en) | Methods and compositions for treating complement-associated disorders | |
MX342613B (es) | Geles con base de acido hialuronico que incluyen agentes anestesicos. | |
UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
UA108885C2 (uk) | Композиція рисперидону для ін'єкційної депо-форми | |
MX2010010026A (es) | Agente para tratar enfermedad. | |
MX369385B (es) | Productos para cicatrizar heridas tisulares. | |
MX2011013201A (es) | Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
NZ588913A (en) | Liver cancer drug | |
MX358491B (es) | Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa. | |
MY173582A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
MX2009010689A (es) | Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales. | |
MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
IN2014DN08598A (es) | ||
EP2490700A4 (en) | EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF | |
MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
WO2011087548A3 (en) | Therapeutic compositions and methods for targeted delivery of active agents | |
MY160572A (en) | A combination composition | |
MX2014011836A (es) | Administracion subcutanea de iduronato-2-sulfatasa. |